| Literature DB >> 31598113 |
Yukari Matsuo-Tezuka1, Yusuke Sasaki1, Toshiki Iwai1, Mitsue Kurasawa1, Keigo Yorozu1, Yoshihito Tashiro1, Michinori Hirata1.
Abstract
Aim: Iron overload is a life-threatening disorder that can increase the risks of cancer, cardiovascular disease, and liver cirrhosis. There is also a risk of iron overload in patients with chronic kidney disease. In patients with renal failure, iron storage is increased due to inadequate iron utilization associated with decreased erythropoiesis and also to the inflammatory status. To evade the risk of iron overload, an accurate and versatile indicator of body iron storage in patients with iron overload is needed. In this study, we aimed to find useful iron-related parameters that could accurately reflect body iron storage in mice in order to construct a murine model of iron overload.Entities:
Year: 2019 PMID: 31598113 PMCID: PMC6778918 DOI: 10.1155/2019/7463047
Source DB: PubMed Journal: Contrast Media Mol Imaging ISSN: 1555-4309 Impact factor: 3.161
Figure 1(a) Representative proton-density-weighted images of livers (indicated by white arrow) on Day 3 after administration of iron-dextran or dextran (control = dextran; Iron 0.1 = 0.1 mg iron-dextran/mouse; Iron 0.5 = 0.5 mg iron-dextran/mouse; Iron 2.5 = 2.5 mg iron-dextran/mouse). (b) R1, (c) R2, and (d)R2 of MRI of livers on Day 3 after administration of iron-dextran or dextran (control = dextran; Iron 0.1 = 0.1 mg iron-dextran/mouse; Iron 0.5 = 0.5 mg iron-dextran/mouse; Iron 2.5 = 2.5 mg iron-dextran/mouse). Results are expressed as mean + SD. Five mice from each group were used. Statistical significances were analyzed by Dunnett's test. P < 0.05.
Figure 2(a) Histopathological analysis for hepatic hemosiderin deposition in iron-loaded mice on Day 3 after administration of iron-dextran or dextran (control = dextran; Iron 0.1 = 0.1 mg iron-dextran/mouse; Iron 0.5 = 0.5 mg iron-dextran/mouse; Iron 2.5 = 2.5 mg iron-dextran/mouse). (b) Liver iron content, (c) serum hepcidin levels, and (d) serum ferritin levels on Day 3 after administration of iron-dextran or dextran (control = dextran; Iron 0.1 = 0.1 mg iron-dextran/mouse; Iron 0.5 = 0.5 mg iron-dextran/mouse; Iron 2.5 = 2.5 mg iron-dextran/mouse). Results are expressed as mean + SD. Five mice from each group were used. Statistical significances were analyzed by Dunnett's test. P < 0.05.
Hemoglobin levels and iron indices in the blood on Day 3 after administration of iron-dextran or dextran (control = dextran group; Iron 0.1 = 0.1 mg iron-dextran/mouse; Iron 0.5 = 0.5 mg iron-dextran/mouse; Iron 2.5 = 2.5 mg iron-dextran/mouse).
| Control | Iron 0.1 | Iron 0.5 | Iron 2.5 | |
|---|---|---|---|---|
| Hemoglobin (g/dL) | 15.0 ± 1.1 | 15.3 ± 1.6 | 15.8 ± 1.5 | 14.3 ± 0.6 |
| Serum iron ( | 152.8 ± 42.7 | 182.8 ± 46.8 | 143.6 ± 27.2 | 184.6 ± 22.0 |
| UIBC ( | 120.0 ± 13.0 | 121.8 ± 22.2 | 140.8 ± 24.3 | 130.6 ± 30.4 |
| TIBC ( | 272.8 ± 35.7 | 304.6 ± 45.8 | 284.4 ± 26.9 | 315.2 ± 27.2 |
Mean ± SD (n = 5); UIBC, unsaturated iron binding capacity; TIBC, total iron binding capacity.
Figure 3Correlations of (a) R1 value obtained from MRI of liver vs. liver iron content, (b) R2 value obtained from MRI of liver vs. liver iron content, and (c) R2 value obtained from MRI of liver vs. liver iron content.
Figure 4Correlations of (a) serum hepcidin level vs. liver iron content and (b) serum ferritin level vs. liver iron content.